Kornimate/medical-research-clean huggingface dataset:
risk stratification with chest ct to rule-out suspected sars-cov-2 infections

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2

Summary: the study objective is to investigate the diagnostic value and consistency of chest ct as compared with comparison to rt-pcr assay in covid-19 in patients which were stratified for hospital admission.

to prevent spreading of the new coronavirus (sars-cov-2) from patients who are infected but in whom infection was not detected by means of reverse transcription polymerase chain reaction (rt-pcr) and who are to be admitted to ordinary wards of hospitals, we aimed to determine validity of exclusion of pneumonia immediately before admission by means of chest computed tomography. patients admitted to the emergency department of the university hospital jena with covid-19 symptoms (temperature \> 37.5°c; respiratory and/or gastrointestinal symptoms) whose rt-pcr test resulted negative, undergo a chest ct scan. those patients without pulmonary infiltrates can be safely ruled out for covid-19. thus, ct has perfect selectivity evidence regarding pulmonary infiltrates; it has limited selectivity concerning the pathogenesis of the infiltration. the study objective is to investigate the diagnostic value and consistency of chest ct as compared with comparison to rt-pcr assay in covid-19 in patients which were stratified for hospital admission. the hypothesis is that chest ct has the greatest clinical evidence (no detection of lung infiltration) when the rt-pct is tested negative. we assume that chest ct has a high sensitivity for diagnosis of respiratory dominant covid-19. a pulmonary covid-19 in epidemic areas can be best ruled out when chest ct is negative for the presence of infiltrations of the lung parenchyma. this is described by the snout principle which is an acronym for 'sensitive test when negative rules out the disease' under the condition of a low pretest probability.

Eligibility criteria:
inclusion criteria: * ≥ 18 years * provided written informed consent * intended hospital admission for any reason * symptoms that suggest infection with sars-cov-2 * participant agrees to rt pcr and antibody test (sars-cov-2) exclusion criteria: * \< 18 years * pregnancy cannot be excluded
ilaprazole for the treatment of gastroesophageal reflux disease (gerd) in chinese patients

Conditions: Gastroesophageal Reflux Disease

Summary: this study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of gerd.


Eligibility criteria:
inclusion criteria: * consenting patients will be eligible for enrollment if they: * are 18-70 years of age, * have at least one of the two symptoms, heartburn and reflux, * have photographically documented erosive esophagitis confirmed by esophagogastroduodenoscopy(egd), and graded according to the los angeles (la) classification (a-d), within 5 days before randomization to treatment. female patients are required to be nonpregnant, nonlactating, postmenopausal, surgically sterilized, or using a medically acceptable form of birth control, as determined by the investigator. women of child- bearing potential will receive a pregnancy test. exclusion criteria: * patients will be ineligible if they: * have cancerous or peptic ulcers, zollinger-ellison syndrome, varices of esophagus or fundus of stomach * have a known history of gastric acid suppression operation, esophageal operation or peptic operation other than simple closure of perforation, * have severe complications, severe other diseases of digestive tract such as crohn's disease and ulcerative colitis, and severe other systemic diseases, * have taken proton pump inhibitors within the 5 days or for more than three consecutive days within the two weeks immediately preceding start of study drug, * participated in a clinical trial with an investigational drug or device within the past three months, * have hypersensitivity or idiosyncratic reaction to ilaprazole, esomeprazole or any other benzimidazole, * have alcoholic intemperance, drug addiction or any other improper habits.

Keywords: gerd
a randomized controlled trial (rct) to determine the efficacy of a multidisciplinary cbt based pain management program for the treatment of aromatase inhibitor associated musculoskeletal symptoms (aimss) in breast cancer survivors

Conditions: Breast Cancer

Summary: the purpose of this research is to evaluate the effectiveness of a multidisciplinary pain management program for aimss in reducing pain, subjective cognitive complaints, psychological distress, and impaired functional status resulting in improved adherence to aromatase inhibitor medications compared to usual care. we want to identify predictors of improvement in pain, functional status, subjective cognition and mood following participation in the program.


Eligibility criteria:
inclusion criteria: * at least 18 years old * ecog ≤ 2 * stage 0-iii hr+ breast cancer in need of strategies to reduce symptoms and improve quality of life exclusion criteria: • less than 18 years of age. - stage 4 hr+ breast cancer
observational study for the evaluation of long-term safety of radium-223 used for the treatment of metastatic castration resistant prostate cancer

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: observational study in the routine clinical practice setting to evaluate the short and long term safety profile of radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.


Eligibility criteria:
inclusion criteria: * treatment decision to radium-223 needs to be made independent from and before patient enrollment in the study * histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases * signed informed consent exclusion criteria: * previously treated with radium-223 for any reason * currently treated in clinical trials including other radium-223 studies * planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use

Keywords: radium-223 crpc phase iv safety study
optimization of hemodynamic conditions during caesarean section under spinal anaesthesia

Conditions: Caesarean Section

Summary: the purpose of this study is to determine wether intravenous phenylephrine, administered as start bolus and following continuous infusion (specific dosage per weight), or optimal lower limb bandaging is more effective in preventing hypotension during caesarean section under spinal anaesthesia in healthy women. the hypothesis is that the phenylephrine model is superior to lower limb compression in preventing hypotension.


Eligibility criteria:
inclusion criteria: healthy women elective caesarean section under spinal anaesthesia informed consent age 18-40 asa 1-2 bmi 18-32 prior to pregnancy height 160-180 cm exclusion criteria: any form of disease or anomalities: heart or vascular disease cerebrovascular disease other somatic or psychiatric disease hypertension or preeclampsia contraindication against spinal anaesthesia anomalities concerning pregnancy and foster

Keywords: hypotension caesarean section spinal anaesthesia lower limb compression / wrapping phenylephrine
the asthma breathing record study

Conditions: Asthma

Summary: the study involves a new device, called 'n-tidal c', which uses a method that has the potential to predict when asthma attacks are about to happen. the device works by accurately measuring an individual's exhaled co2 waveform. a person has to breathe in and out through the mouthpiece at their normal relaxed rate of breathing. it does not need any extra effort and therefore has considerable benefits over current breathing tests which require significant patient effort.

people with more severe asthma suffer from frequent asthma attacks that require regular hospital admissions. these attacks are difficult to predict and can devastate the lives of patients. a new tool is needed that can help to predict when an asthma attack is going to happen. this would help people recognise an attack earlier and allow treatment to be started sooner. this study will evaluate a new breathing monitor, to see whether it can detect asthma attacks. the study tests a new device, called 'n-tidal c', which uses a method that has the potential to predict when attacks are about to happen. the investigators have found that people with asthma breathe out a gas, called carbon dioxide (co2), in a different way to healthy people. the pattern of breathing out co2 (the waveform) changes further when patients are having an attack of their disease. if patients could monitor their co2, they may recognise when their asthma is getting worse, and take earlier action to avoid attacks getting out of hand and going to hospital.

Eligibility criteria:
inclusion criteria: 1. male or female, aged ≥7 years. 2. confirmed clinician diagnosis of asthma by examination of medical records, and based on accepted national and/or international criteria e.g. bts/sign, or gina. 3. moderate or severe asthma (defined as bts stage 2-5) 4. poorly controlled asthma (defined as an acq score of ≥1) 5. exacerbation prone asthma (defined as at least 1 asthma exacerbation requiring oral corticosteroid treatment in the last 12 months). 6. providing written informed consent, or parental/guardian consent and participant assent in the case of a child exclusion criteria: 1. inability to understand or comply with study procedures and/or inability to give fully informed consent. 2. known other lung, chest wall, neuromuscular, cardiac or other comorbidity or abnormality that would affect spirometry and/or other measures of lung function or tbco2 measurements (including breathing pattern disorder or chronic obstructive pulmonary disease). 3. smokers (current or ex-smokers) with a \>10 pack year history. 4. in the opinion of the clinical investigator, the participant would have difficulty completing the study procedures consistently (for example, difficulty holding the device, or long periods of absence/travel) throughout the study period.
description of septic thrombophlebitis on central venous catheter and midline

Conditions: Septic Thrombophlebitis

Summary: central venous catheters improve the tolerability and feasibility of patient care in the hospital setting by allowing the administration of hyper-osmotic, vesicant and venotoxic fluids. despite these advantages, the long-term presence of central venous catheters is associated with thrombotic and infectious risks , including catheter-related bacteremia, which can be complicated by septic thrombophlebitis and endocarditis that can lead to death. septic thrombophlebitis is a complication of venous catheter infections, which increases the morbidity. it is defined by the presence of a thrombosis in the vein where the venous catheter is located, associated with a bacteremia. a distinction is made between superficial and deep thrombophlebitis. the frequency of septic thrombophlebitis of venous catheters is variable and poorly described in the literature. when the diagnosis of septic thrombophlebitis is made, it is recommended to extend the duration of antibiotic therapy, to remove the infected catheter and to prescribe anticoagulant treatment. however, there is no recommendation on the duration of anticoagulation for septic thrombophlebitis, whether it is deep or superficial. investigator proposes a prospective and descriptive interventional study to describe the ultrasound evolution of thrombus in patients with septic thrombophlebitis on central venous catheter and midline.


Eligibility criteria:
inclusion criteria: * adult patient hospitalised at the chm or chua, with a central venous device (implantable chamber, central venous jugular, femoral, subclavian, piccline, dialysis catheter) or a midline and having catheter-related bacteremia * catheter-related bacteremia according to the following definition (epopi): positive blood cultures within 48 hours of a suspected catheter infection (or its removal) with one of the following criteria: - before catheter removal: differential time of positivity of central/peripheral blood cultures ≥ 2 hours * after catheter removal: positive catheter culture ≥ 103 cfu/ml, with the same organism. * patient transportable for ultrasound or ultrasound can be performed in the patient's bed * patient capable of giving consent, or consent of the trusted person for patients not capable of giving consent at the time of inclusion * written consent signed by the participant and the investigator * person affiliated to social security exclusion criteria: * patient with a life expectancy of less than one month * contraindication to anticoagulation * patient already on curative anticoagulant therapy for any indication * minor or adult patient under guardianship or protected or deprived of liberty * pregnant, nursing or parturient woman

Keywords: septic thrombophlebitis doppler ultrasound
efficacy of tranexamic acid (txa) in humerus orif

Conditions: Fracture Humerus

Summary: the purpose of this study is to determine if administration of tranexamic acid (txa), a clotting agent, will decrease blood loss, the need for transfusion, and reduce the likelihood of wound complications such as infection. investigators will also see if the drug can effectively decrease operative time and length of hospitalization.

single-center randomized controlled trial, parallel two-arm design allocation 1:1 exposed-control design to determine if txa aids in prevention of blood loss in upper extremity trauma, specifically humerus fractures. patient population includes male and female adults with no history of thromboses who suffered an isolated humeral injury. patients will be evaluated at allegheny general hospital (agh) as surgical candidates and allocated to the exposure group (receive txa) or the control group (saline placebo). patients randomized to treatment arm of study will have txa administered 10 minutes prior to surgery. the control group will have saline administered 10 minutes prior to surgery. patients will be seen in follow up at both 2 weeks and 6 weeks postoperatively, as well as followed through the electronic medical record (emr).

Eligibility criteria:
inclusion criteria: 1. males or females age 18-100 years 2. isolated proximal humerus or humeral shaft fracture undergoing open reduction internal fixation. 3. must be able to read and understand english and consent for themselves. exclusion criteria: 1. allergy to txa. 2. acquired disturbances of color vision. 3. history of arterial or venous thromboembolic disease; such as dvt, pe, cva, tia. 4. pregnant or breastfeeding. 5. recent mi (within 6 months of surgery) or any placement of stent regardless of time since placement. 6. renal impairment (creatinine above 1.2 in women, creatinine above 1.4 in men) 7. refusal of blood products 8. subarachnoid hemorrhage 9. disseminated intravascular coagulation

Keywords: open reduction internal fixation blood loss
clinical study on efficacy and safety of hetrombopag in the preoperative patients of thrombocytopenia

Conditions: Thrombocytopenia

Summary: this is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery

it was planned to include 55 patients with immune thrombocytopenia with preoperative platelet ≤75×10\^9/l. after signing the informed consent letter, the patients will enter the screening period (up to 7 days), and after passing the screening, they will receive oral hexapopal treatment, the specific medication regimen is: 7.5mg, once a day, taken orally on an empty stomach before going to bed, for a maximum of 14 days, and stop the drug when plt≥100×10\^9/l. during the oral administration of hexapopal, the administration was suspended when plt≥200×10\^9/l, and continued when the blood image was monitored weekly until plt \< 100×10\^9/l. during the treatment period, blood routine was monitored every 7 days, and when plt≤30×10\^9/l or ≥300×10\^9/l, blood routine was monitored every 3 days. patients will have an end-of-treatment visit within 7 days of stopping treatment, followed by a 30-day safe follow-up period.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old; diagnosis of immune thrombocytopenia. 2. platelets ≤75×10\^9/l before scheduled elective surgery. exclusion criteria: 1. history of allergy to thrombopoietin receptor agonists (tpo-ra) drugs; 2. severe bleeding symptoms, such as gastrointestinal bleeding, bleeding of important organs, and intracranial bleeding; 3. thrombotic diseases, such as pulmonary embolism, arterial thrombosis and disseminated intravascular coagulation (dic); 4. positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody; 5. new york heart association (nyha) grade 3 or 4 congestive heart failure; 6. history of angina pectoris, myocardial infarction or cerebral infarction within 6 months before the screening period; 7. have an active infection that is difficult to control; 8. pregnant or lactating women; 9. other conditions determined by the investigator to be unsuitable for inclusion in the study

Keywords: hetrombopag thrombocytopenia preoperative
locally advanced nsclc treated with radiochemotherapy: phase 2 study on the value of a stereotactic boost

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a monocentric, non-randomized, open-label, superiority phase ii clinical investigation evaluating the efficacy of additional cyberknife irradiation after a doublet of platinum salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (nsclc), with an interim analysis.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 years old or more 2. ecog 0 to 2 3. histologically proven non-small cell lung cancer 4. stage iii non-metastatic tumor, not allowing for immediate surgery 5. volume(s) on the evaluation scan after neoadjuvant treatment meeting the following criteria: * 1 to 3 target volumes of less than 5 cm in greatest diameter * and enabling additional irradiation to be carried out in compliance with the manufacturer requirements and with the doses delivered to the organs at risk (oar/fractions) defined in appendix 2 6. patients who have received a " taxcis " treatment consisting in 2 cycles of induction chemotherapy (platinium-based doublet) and then at least 40 gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet) 7. no contraindication to implantable venous devices (ivds) 8. patient who has read the patient information note and signed the consent form 9. if applicable, negative pregnancy test\* 10. eligible for national health insurance in france exclusion criteria: 1. positive egfr mutation 2. exercise-induced dyspnea associated with heart failure equal to or greater than stage iii of the new york heart association (nyha) classification, (appendix 3) 3. coronary syndrome or heart failure in the last three months 4. pulmonary function test contraindicating radiotherapy: pft-fev1 inferior to 1 l. 5. after radio-chemotherapy, presence of any toxicity contraindicating cyberknife irradiation 6. vulnerable populations and participants as defined in articles 64 to 68 of regulation (eu) 2017/745 of the european parliament and of the council of 5 april 2017: * incapacitated participants who have not given or refused informed consent prior to the onset of their incapacity, who are not under the provisions of article 64 ; * pregnant or breast-feeding women who are not covered by the provisions of article 66 ; * adults under legal protection or unable to express their consent.
increasing vaccine uptake in underresourced public housing areas

Conditions: Coronavirus; Vaccine Refusal

Summary: this proposal seeks to enhance uptake and completion of covid-19 vaccination among african american and latinx public housing residents in south los angeles. given the multiple disparities experienced by public housing residents, the investigators will utilize a theoretically-based, multidisciplinary and culturally tailored intervention to provide education at multiple levels and implement innovate strategies to engage this population in the uptake of covid-19 vaccination.

one particular group, african american and latinx public housing residents, are facing adverse effects related to worsening social determinants and health disparities. utilizing a community-driven approach, the overall objective of this proposed study is to increase covid-19 vaccine uptake and completion the impact of covid-19 among african american and latinx public housing residents. guided by the community based participatory model, the information, motivation, and behavioral skills (imb) and the transtheoretical model will be utilized to carry out this intervention. through this innovative program, we will establish academic-community team for improving vaccine acceptability and targeted engagement (activate) program, which will develop leadership triads of public housing resident leaders, nurse practitioner students, and public health students to carry out this multilevel intervention.

Eligibility criteria:
aim 2: inclusion criteria: * identify as latinx or african american * age 18 or older * reside in one of the six collaborating public housing area * speak either english or spanish exclusion criteria: * not a resident at one of the collaborating public housing areas * does not self-identify as african american or latinx * age 17 and younger * unable to speak either english or spanish aim 3: inclusion criteria: * identify as latinx or african american * age 18 or older * reside in one of the six collaborating public housing area * speak either english or spanish * report vaccine hesitancy exclusion criteria: * not a resident at one of the collaborating public housing areas * does not self-identify as african american or latinx * age 17 and younger * unable to speak either english or spanish * received all recommended vaccines for covid-19 * no reporting of vaccine hesitancy
bilirubin levels to diagnose appendicitis and predict appendiceal perforation

Conditions: Acute Appendicitis; Appendicitis Perforated

Summary: the goal of this study is to learn if serum bilirubin levels can aid in the diagnosis of acute appendicitis and predict appendiceal perforation

the study aims to assess hyperbilirubinemia: serum direct, indirect and total bilirubin to enhance the diagnostic accuracy of acute appendicitis. also it aims to analyze different patient variables such as age, gender, duration of symptoms, leukocyte and neutrophil count, alvarado score, presence of fever, nausea \& vomiting, peritonitis alongside serum total bilirubin level in patients with appendicitis and assess which variables can be taken as independent factors to predict appendiceal perforation.

Eligibility criteria:
inclusion criteria: * patients of age group above 5 years with acute appendicitis undergoing appendectomy with written informed consent. exclusion criteria: * patients with appendicular lump. * patients with acute and chronic liver diseases like acute hepatitis, hemolytic disease, gilbert's syndrome, dubin-johnson syndrome, alcoholic liver disease. * acquired or congenital biliary disease. * history of hepatotoxic drugs.

Keywords: single-center prospective cross-sectional